Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Bioventus Inc. reported strong second-quarter 2026 results, with net sales of $153.2 million, up from $147.7 million a year earlier. Net income attributable to Bioventus rose to $33.4 million from $7.5 million, aided in part by removal of a $24.6 million valuation allowance on deferred tax assets. GAAP diluted EPS increased to $0.47 from $0.11, while non-GAAP diluted EPS was $0.22 versus $0.21. Adjusted EBITDA reached $35.3 million, compared with $33.8 million, and cash from operations was $19.9 million.
The company made a discretionary $20.0 million principal prepayment on its term loan, reducing long-term debt and future interest expense. For full-year 2026, Bioventus reaffirmed guidance for net sales of $600–$610 million, adjusted EPS of $0.75–$0.79, and cash from operations of $84–$89 million. Following a recent unsolicited acquisition proposal and other expressions of interest, the board formed an independent committee, advised by Evercore and Latham & Watkins, to review strategic alternatives, including a potential sale or continued standalone execution, with no timetable or assurance of any transaction.
BlackRock, Inc. reported a passive ownership stake in Bioventus Inc. (Class A Stock) on a Schedule 13G. BlackRock and certain of its subsidiaries and affiliates beneficially owned 3,404,523 shares of Bioventus Class A stock, representing 5.02% of the class.
BlackRock had sole voting power over 3,350,552 shares and sole dispositive power over all 3,404,523 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Bioventus’ outstanding common shares. The schedule is signed by a Managing Director of BlackRock, with related exhibits including a Power of Attorney and identification of relevant subsidiaries.
Bioventus Inc. director and 10% owner John A. Bartholdson reported equity compensation and vesting-related transactions with no open-market buying or selling. He received a grant of 25,146 restricted stock units, each representing one share of Class A common stock, at no cash cost.
On a prior date, 32,282 restricted stock units vested and were exercised into 32,282 shares of Class A common stock, leaving no units remaining from that award and resulting in 111,902 directly held shares. He also reports indirect ownership of 6,939,357 shares through Juniper investment entities, over which he shares voting and dispositive power and disclaims beneficial ownership beyond his pecuniary interest. The new RSU grant will vest on the earlier of the day immediately preceding the first Annual Meeting of Stockholders after grant or the first anniversary of grant, subject to continued board service.
Bioventus director and 10% owner Martin P. Sutter reported equity compensation and related share movements. On June 3, 2026, he received a grant of 25,146 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock, scheduled to vest based on future board service conditions. On June 2, 2026, 32,282 RSUs vested and were exercised, delivering the same number of Class A shares and bringing his direct Class A holdings to 117,523 shares. The filing also shows 13,021,324 Class A shares held indirectly through EW Healthcare Partners Acquisition Fund, L.P. and White Pine Medical, LLC, where Sutter is one of several managers; these managers disclaim beneficial ownership except to the extent of their pecuniary interests.
Bioventus Inc. director Susan M. Stalnecker reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 3, 2026, she received a grant of 25,146 RSUs, each representing a contingent right to one share of Class A common stock.
On June 2, 2026, 32,282 RSUs vested and were exercised into 32,282 shares of Class A common stock at no cash exercise price. Following these transactions, she holds 138,239 shares of Class A common stock directly, along with 25,146 RSUs that will vest based on future service conditions.
Bioventus Inc. director Guy P. Nohra reported equity compensation activity consisting of a new grant of restricted stock units and the vesting of a prior award. On June 3, 2026, he received 25,146 restricted stock units, each representing a contingent right to one share of Class A common stock. On June 2, 2026, 32,282 restricted stock units vested and were exercised into 32,282 shares of Class A common stock, leaving him with 148,892 shares held directly after the transactions. These filings reflect routine equity awards and vesting rather than open-market purchases or sales.
Bioventus Inc. director Guido J. Neels reported routine equity compensation activity. On June 3, 2026, he received a grant of 25,146 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock, subject to future vesting conditions tied to board service. On June 2, 2026, a prior RSU award for 32,282 units vested and was exercised, converting into 32,282 shares of Class A common stock at no cash cost. Following these transactions, he directly holds 117,523 shares of Class A common stock, with the exercised RSU award fully settled.
Bioventus Inc. director Michelle McMurry-Heath reported equity compensation and a vesting event. On June 2, 2026, 32,282 restricted stock units were exercised and converted into the same number of shares of Class A common stock, leaving her with 77,279 shares held directly. Each RSU represents a contingent right to receive one share of Class A common stock, and the RSUs referenced in the footnotes vest based on service on the Board and the timing of the company’s annual stockholder meeting. On June 3, 2026, she also received a grant of 25,146 RSUs as additional equity compensation, which will vest according to the disclosed schedule.
Bioventus Inc. director Mary Kay Ladone reported equity compensation and an option-style exercise of prior awards. On June 3, 2026 she received a grant of 25,146 Restricted Stock Units (RSUs), each representing the right to receive one share of Class A common stock. On June 2, 2026, 32,282 RSUs vested and were exercised into 32,282 shares of Class A common stock, increasing her direct holdings to 111,263 shares. The newly granted RSUs will vest based on continued board service through the earlier of the company’s next Annual Meeting of Stockholders or the first anniversary of grant.